Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
The in vitro spectrum of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), was compared with that of ciprofloxacin, levofloxacin, and trovafloxacin against 736 clinical isolates from cancer patients. Garenoxacin was the most active agent overall against Gram-positive organisms, with potent activity against Aerococcus spp., Micrococcus spp., Rhodococcus equi, Stomatococcus mucilaginous, Bacillus spp., Enterococcus faecalis, Listeria monocytogenes, methicillin-susceptible Staphylococcus spp., and all beta-hemolytic and viridans streptococci. Although ciprofloxacin was the most active agent tested against the Enterobacteriaceae garenoxacin inhibited the majority of these isolates at <or=4.0 microg/ml, its proposed susceptibility break-point. All 4 agents had sub-optimal activity against Pseudomonas aeruginosa and variable activity against other non-fermenters, with Stenotrophomonas maltophila and Alcaligenes spp. being the most resistant isolates. The overall broad spectrum of garenoxacin warrants its evaluation for the prevention or treatment of infections in cancer patients.
Rolston
Kenneth V I
KV
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA. krolston@mail.mdanderson.org
Frisbee-Hume
Susan
S
LeBlanc
Barbara M
BM
Streeter
Harriet
H
Ho
Dah H
DH
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D005260:Female; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D007211:Indoles; D064704:Levofloxacin; D008297:Male; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology; D015242:Ofloxacin / Q000494:pharmacology; D015363:Quinolones; D012680:Sensitivity and Specificity
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D007211:Indoles; D009287:Naphthyridines; D015363:Quinolones; D002939:Ciprofloxacin; D064704:Levofloxacin; C080163:trovafloxacin; D015242:Ofloxacin; C419689:garenoxacin